An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer
Launched by EPIMMUNE · Feb 13, 2003
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed diagnosis of Colon Cancer, stage III
- • At least four weeks following prior standard treatment, with no evidence of disease
- • Must use adequate birth control
- Exclusion Criteria:
- • Prior cancer vaccine therapy or concurrent participation in any other investigational study
- • A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment
- • A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine
- • Women who are pregnant, intend to become pregnant, or who are breast feeding
About Epimmune
Epimmune is a biopharmaceutical company dedicated to advancing the development of innovative immunotherapies for the treatment of cancer and infectious diseases. With a focus on harnessing the power of the immune system, Epimmune employs cutting-edge technologies to create personalized therapeutic solutions designed to elicit robust and durable immune responses. Committed to scientific excellence and patient-centric approaches, the company actively engages in clinical trials to evaluate the safety and efficacy of its novel candidates, aiming to transform the landscape of immunotherapy and improve outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Dallas, Texas, United States
Tyler, Texas, United States
Seattle, Washington, United States
Orlando, Florida, United States
Spokane, Washington, United States
Albany, New York, United States
Los Angeles, California, United States
San Diego, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials